drugset / Trial / NCT04786340
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
Phase 2
Completed
58 enrolled
WinSanTor, Inc
Eastern Virginia Medical School · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2022-12-08
- Completion
- 2022-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirenzepine | Small molecule | 4 ml | Topical |
| Subject | Pirenzepine | Small molecule | 146 mg | Topical |